About DS7300-188
A Phase 3, Multicenter, Randomized, Open Label Study Of Ifinatamab Deruxtecan (I Dxd), A B7-H3 Antibody Drug Conjugate (Adc), Versus Treatment Of Physician’s Choice (Tpc) In Subjects With Relapsed Small Cell Lung Cancer (Sclc). This app is specifically intended for participants in the ds7300-188 study only.
Similar Apps
Medable
Medable is on a mission to enable effective therapies to people faster....
J1I-MC-GZQD
This app has been exclusively created for participants in the medical study...
Avanti
For invited Avanti study participants. You will use this app to consent...
GSK 219685
This app has been created exclusively for participants in the medical study...
GSK 219855 France
You are invited to participate in the GSK BLISSc-ILD OLE study. This...
GSK 221458
This app is specifically intended for participants in the GSK 221458 study...
